Hansa Medical’s Capital Market Days provide an update on number of patients included in the company’s kidney transplantation and anti-GBM studies
Hansa Medical AB (Nasdaq Stockholm: HMED), a biopharmaceutical company focusing on novel immunomodulatory enzymes, today announced that on its Capital Markets Days in Stockholm (today, October 3) and London (October 4), the company will present an update on the number of patients included in the company’s clinical studies.
The update will present the status of the ongoing clinical Phase II studies with the lead drug candidate IdeS in kidney transplantation, where the number of patients treated with IdeS prior to kidney transplantation now amounts to 42. The ongoing studies are expected to be fully enrolled during 2017.
Hansa Medical has previously announced that the first patient has been treated with IdeS in the investigator initiated Phase II study in severe anti-GBM antibody disease. Today’s update will provide the information that in total two patients have been included in the study, both responded favorably. Prior to site initiation of the ongoing study, three patients were treated on named patient basis in Sweden. IdeS appears to be well tolerated in these patients so far.
Hansa Medical will also give an update on the company’s cash position as of September 30, amounting to SEK 131 million, as compared with SEK 170 million at the end of second quarter 2017.
The Capital Market Day in Stockholm will be held at Wallenbergsalen, IVA Konferenscentrum, Grev Turegatan 16, and the event in London will be held at the offices of FTI Consulting, 200 Aldersgate, EC1A 4HD. Both events will be webcast and available on the company’s website www.hansamedical.com.
The meeting will include data from studies with lead product IdeS published in The New England Journal of Medicine (August 3, 2017). Co-lead authors Dr Stanley Jordan from Cedars-Sinai Medical Center, Los Angeles, and Dr Tomas Lorant from Uppsala University Hospital, Sweden will present.
Senior management from Hansa Medical, including Göran Arvidson, Dr Christian Kjellman, Dr Lena Winstedt, Dr Sam Agus, Henk Doude van Troostwijk and Emanuel Björne will present in-depth talks on the company, the market and their proprietary products.
- Introduction to Hansa Medical and IdeS
- Opportunities for IdeS in transplantation and beyond, including cancer immunotherapy
- Kidney transplantation and HLA-sensitization in the US and Europe
- Discussion of the results with IdeS published earlier in The New England Journal of Medicine
IdeS – A potential game changer in transplantation
- The path to approval
- Commercialization strategy in transplantation
- IdeS beyond desensitization – Potentially an even greater opportunity
- Novel IgG cleaving enzymes under development
- Q&A and closing remarks
If you would like to register, please contact Annika Nielsen at email@example.com for the Stockholm event and Hanna Skeppner at firstname.lastname@example.org for the London event.
This information is information that Hansa Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 8:30 AM CEST on October 3 2017.
Hansa Medical AB (Publ)
Emanuel Björne, Vice President Business Development and Investor Relations
Göran Arvidson, President and CEO
Mobile: +4670633 3042
Cord Communications, Stockholm
Lars Wahlström Mobile: +46 73 434 0771
FTI Consulting, London
Julia Phillips / Stephanie Cuthbert / Hanna Skeppner: +44 203 727 1000
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead project IdeS is a proprietary antibody-degrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and acute autoimmune indications. The company also has a strong pipeline of preclinical assets that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing translating the Hansa Medical technology into relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, its shares (ticker: HMED) are listed on Nasdaq Stockholm.